Intrathecal nusinersen treatment for SMA in a dedicated neuromuscular clinic: an example of multidisciplinary and integrated care

被引：0
作者：
Valeria A Sansone
Emilio Albamonte
Francesca Salmin
Jacopo Casiraghi
Alice Pirola
Massimo Bettinelli
Fabrizio Rao
Luca Mancini
Nicola Tovaglieri
Fausto Fedeli
Paolo Stoia
Maurizio Heinen
Valeria Cozzi
Elena Carraro
Christian Lunetta
Alessandra Di Bari
Eugenio Mercuri
机构：
[1] University of Milan,Neurorehabilitation Unit, the NEMO Clinical Center in Milan
[2] Dept of Pediatrics,Child Neurology Department, the NEMO Clinical Center
[3] ASST Niguarda,undefined
[4] Policlinico Universitario “A. Gemelli”,undefined
来源：
Neurological Sciences | 2019年 / 40卷
关键词：
Spinal muscular atrophy; Nusinersen; Multidisciplinary; Integrated care; Spinraza;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Nusinsersen is now available in Italy for all SMA types. We describe the experience with intrathecal treatment with nusinersen in 50 patients with SMA at the NEMO Center (NEuroMuscular Omniservice Clinical Center) in Milan, a neuromuscular patient-centered clinic hosted within Niguarda Hospital, a National Public General Hospital. Our results indicate that the pathway of care described outweighs the burden due to the repeated intrathecal injections. Irrespective of age and severity, the treatment is feasible, accessible, and replicable provided that there is a multidisciplinary team having experience and training in SMA.
引用
收藏
页码：327 / 332
页数：5
相关论文
共 207 条
  • [1] Kolb SJ(2017)Natural history of infantile-onset spinal muscular atrophy Ann Neurol 82 883-891
  • [2] Coffey CS(2018)Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4 Eur J Neurol 25 512-518
  • [3] Yankey JW(2017)218th ENMC International Workshop: revisiting the consensus on standards of care in SMA Naarden, The Netherlands, 19-21 February 2016 Neuromuscul Disord 27 596-605
  • [4] Krosschell K(2018)Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care Neuromuscul Disord 28 103-115
  • [5] Arnold WD(2018)Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics Neuromuscul Disord 28 197-207
  • [6] Rutkove SB(2017)Nusinersen versus sham control in infantile-onset spinal muscular atrophy N Engl J Med 377 1723-1732
  • [7] Swoboda KJ(2015)A large animal model of spinal muscular atrophy and correction of phenotype Ann Neurol 77 399-4147
  • [8] Reyna SP(2017)FDA-approved oligonucleotide therapies in 2017 Mol Ther 25 1069-1075
  • [9] Sakonju A(2018)Single-center experience with intrathecal administration of Nusinersen in children with spinal muscular atrophy type 1 Eur J Paediatr Neurol 22 122-127
  • [10] Darras BT(2017)Expanded access program with Nusinersen in SMA type I in Italy: strengths and pitfalls of a successful experience Neuromuscul Disord 27 1084-1086
12345678910